O'Brien Rebecca Flynn
Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, Tufts University School of Medicine, The Floating Hospital for Children at Tufts-New England Medical Center, Boston, MA 02111, USA.
Adolesc Med Clin. 2006 Oct;17(3):673-85; abstract xi. doi: 10.1016/j.admecli.2006.06.004.
This article reviews the current status of microbicide development and challenges faced in developing safe and effective compounds. The ever growing HIV pandemic, lack of effective vaccines against HIV and other sexually transmitted infections, concern about the vulnerability of women, and difficulty in condom negotiation are factors that drive the development of topical microbicides as a prophylactic method for women. The ideal microbicide needs to be safe and highly effective and not increase viral resistance or cause disruption of host defenses. Advances in the understanding of HIV transmission and the role of other sexually transmitted infections have allowed progress in development of microbicide candidates as clinical trials of potential agents are awaited.
本文综述了杀微生物剂的研发现状以及在开发安全有效化合物过程中所面临的挑战。不断蔓延的艾滋病疫情、缺乏针对艾滋病毒和其他性传播感染的有效疫苗、对女性易感染性的担忧以及在协商使用避孕套方面存在的困难，这些因素推动了局部用杀微生物剂作为女性预防方法的研发。理想的杀微生物剂需要具备安全性和高效性，且不会增加病毒耐药性或破坏宿主防御机制。随着对艾滋病毒传播以及其他性传播感染作用的认识不断深入，杀微生物剂候选药物的研发取得了进展，目前正等待潜在药物的临床试验结果。
